Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy

Objectives:  The prospective study was designed to clarify the impact of CYP2C19 on quadruple therapies and survey the efficacies of rabeprazole‐based quadruple therapy for Helicobacter pylori infection after failure of standard triple therapies.

[1]  J. Wu,et al.  Levofloxacin‐Containing Triple Therapy to Eradicate the Persistent H. pylori after a Failed Conventional Triple Therapy , 2007, Helicobacter.

[2]  G. Sachs,et al.  The Gastric H,K ATPase as a Drug Target: Past, Present, and Future , 2007, Journal of clinical gastroenterology.

[3]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[4]  S. Miehlke,et al.  Effective regimens for the treatment of Helicobacter pylori infection , 2006, Expert opinion on investigational drugs.

[5]  R. Hunt,et al.  The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis , 2006, The American Journal of Gastroenterology.

[6]  S. Miehlke,et al.  Relevance of Cytochrome P450 Polymorphisms in the Treatment of Helicobacter pylori Infection and Gastroesophageal Reflux Disease , 2006 .

[7]  K. Chu,et al.  Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second‐line treatment of resistant Helicobacter pylori infection , 2006, Alimentary pharmacology & therapeutics.

[8]  Y. Yamaoka,et al.  A Prospective Randomized Trial of Esomeprazole- versus Pantoprazole-Based Triple Therapy for Helicobacter pylori Eradication , 2005, The American Journal of Gastroenterology.

[9]  C. O'Morain,et al.  Treatment of Helicobacter pylori , 2005, Helicobacter.

[10]  A. Kao,et al.  Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism , 2005 .

[11]  G. Anagnostopoulos,et al.  Esomeprazole versus Omeprazole for the Eradication of Helicobacter pylori Infection: Results of a Randomized Controlled Study , 2004, Journal of clinical gastroenterology.

[12]  U. Klotz,et al.  CYP2C19 polymorphism and proton pump inhibitors. , 2004, Basic & clinical pharmacology & toxicology.

[13]  G. Spengler,et al.  Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin-susceptible and-resistant Helicobacter pylori. , 2004, International journal of antimicrobial agents.

[14]  Y. Lo,et al.  Evaluation of a newly developed office-based stool test for detecting Helicobacter pylori: an extensive pilot study. , 2003, Hepato-gastroenterology.

[15]  F. Mégraud,et al.  Second‐line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies , 2003, Alimentary pharmacology & therapeutics.

[16]  H. Chern,et al.  Time‐Dependent Amplified Pharmacokinetic and Pharmacodynamic Responses of Rabeprazole in Cytochrome P450 2C19 Poor Metabolizers , 2003, Pharmacotherapy.

[17]  N. Enomoto,et al.  Is antimicrobial susceptibility testing necessary before second‐line treatment for Helicobacter pylori infection? , 2003, Alimentary pharmacology & therapeutics.

[18]  J. Dent.  Review article: pharmacology of esomeprazole and comparisons with omeprazole , 2003, Alimentary pharmacology & therapeutics.

[19]  D. Graham,et al.  Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island , 2002, American Journal of Gastroenterology.

[20]  A. Pera,et al.  Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy , 2002, Alimentary pharmacology & therapeutics.

[21]  角田 明良,et al.  結腸癌術後の早期離床・早期経口摂取に関するProspective Randomized Trial , 2002 .

[22]  P. Malfertheiner,et al.  Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report , 2002, Alimentary pharmacology & therapeutics.

[23]  T. Matsui,et al.  Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes , 2001, Alimentary pharmacology & therapeutics.

[24]  H. Matsumaru,et al.  A Novel Action of the Proton Pump Inhibitor Rabeprazole and Its Thioether Derivative against the Motility of Helicobacter pylori , 2000, Antimicrobial Agents and Chemotherapy.

[25]  N. Lehn,et al.  Secondary Resistance Among 554 Isolates of Helicobacter pylori After Failure of Therapy , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[26]  A. Mukhopadhyay,et al.  High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong , 2000, Alimentary pharmacology & therapeutics.

[27]  T. Andersson,et al.  Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects , 2000, European Journal of Clinical Pharmacology.

[28]  Williams,et al.  Review article: the pharmacology of rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[29]  D. Faigel,et al.  Effectiveness of Helicobacter pylori therapies in a clinical practice setting. , 1999, Archives of internal medicine.

[30]  G. Sachs,et al.  Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents* , 1997, The Journal of Biological Chemistry.

[31]  J. Crabtree,et al.  In-vitro activity of lansoprazole against Helicobacter pylori. , 1997, The Journal of antimicrobial chemotherapy.

[32]  J. Goldstein,et al.  Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. , 1997, Pharmacogenetics.

[33]  K. Kobashi,et al.  Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. , 1995, Biological & pharmaceutical bulletin.

[34]  Kaoru Kobayashi,et al.  Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status , 1995, Clinical pharmacology and therapeutics.

[35]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[36]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[37]  T. Ishizaki,et al.  Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. , 2005, Drug metabolism and pharmacokinetics.

[38]  K. Yokota,et al.  HELICOBACTER PYLORI INFECTION: CYP2C19 GENOTYPE AND SERUM FERRITIN Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype , 2002 .

[39]  P. Malfertheiner.  European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection. The Maasticht 2-2000 Consensus Report , 2002 .